Roidipedia.Compound reference & reporting
02 OCT 2026
/
Trial data

Enobosarm's PLATEAU trial completes enrollment: a SARM tested to preserve muscle during semaglutide weight loss

Veru finished enrolling roughly 200 adults aged 65 and older in a Phase 2b trial pairing the SARM enobosarm with semaglutide, with interim data due Q1 2027.

enwy27 Jul0 comments
Regulation

FDA advisory panel recommends six peptides — including BPC-157 and TB-500 — for the 503A compounding list

At its July 23–24, 2026 meeting, the Pharmacy Compounding Advisory Committee backed six of seven nominated peptides for the 503A bulk-substances list, but the votes are non-binding and formal rulemaking is still required before compounding can resume.

enwy24 Jul0 comments
Trial data

Retatrutide's TRIUMPH-2 and TRIUMPH-3 report up to 22.6% weight loss in type 2 diabetes and established cardiovascular disease

Eli Lilly's topline results from two more phase 3 trials of the triple agonist met their primary endpoints, with a higher adverse-event discontinuation rate in the cardiovascular-disease cohort.

enwy23 Jul0 comments

Latest

All coverage →
15 Apr
Analysis

BPC-157 and TB-500: the 'healing peptide' hype versus the human evidence

Two injury-recovery peptides dominate fitness TikTok, but the human clinical data behind them is essentially nonexistent.

enwy0 commentsPartly confirmedPartly confirmedThe central claim is traced to a cited source, but some specific figures or details in this piece could not be independently confirmed. Details that fall into that category are marked in the text.Specifically unconfirmedEfficacy claims for both peptides are supported mainly by animal data; human clinical evidence is minimal to absent, so all human-benefit claims are marked partial/unconfirmed. Contamination and mislabeling figures come from clinician reporting of third-party testing rather than a single peer-reviewed dataset.
5 Mar
Analysis

Tongkat ali and fadogia agrestis went viral as 'natty test boosters' — only one has human safety data

A podcast-driven supplement stack pairs a herb with real randomised trials against one whose entire evidence base is a handful of rat studies, some showing organ toxicity.

enwy0 commentsPartly confirmedPartly confirmedThe central claim is traced to a cited source, but some specific figures or details in this piece could not be independently confirmed. Details that fall into that category are marked in the text.Specifically unconfirmedTongkat ali human RCTs and the LiverTox rating/case report are confirmed (LiverTox NBK609015 fetched directly). Fadogia agrestis claims — no human studies, rat testosterone rise plus 28-day testicular/organ toxicity from a single research group, and the Huberman podcast as the popularity driver — are corroborated across multiple secondary summaries but not verified against the original University of Ilorin rodent papers; confidence set PARTIAL accordingly.
15 Dec
Analysis

Methylene blue: a century-old dye goes viral for longevity claims it can't support

Biohackers and celebrities have made the blue liquid a TikTok fixture, but there is no clinical evidence for the cognitive and anti-aging claims — and a real drug-interaction risk.

enwy0 commentsUnconfirmedUnconfirmedThis is being reported by the cited source, but we have not been able to confirm it independently. It is published because it is worth knowing about, not because it has been established. Treat it as a report, not a fact.Specifically unconfirmedLongevity and cognitive-enhancement claims are unconfirmed in humans; only preclinical/laboratory data exist. RFK Jr.'s blue liquid was never confirmed to be methylene blue. The ~13% SSRI-use figure is reporting-sourced.
1 Dec
Analysis

'Tren' culture meets the data: survey links trenbolone to greater psychological distress

A 2024 study in the International Journal of Drug Policy examined the compound that steroid-using communities themselves rate as the most mentally harmful.

enwy0 commentsPartly confirmedPartly confirmedThe central claim is traced to a cited source, but some specific figures or details in this piece could not be independently confirmed. Details that fall into that category are marked in the text.Specifically unconfirmedCardiovascular and neurotoxicity claims rest on case reports, self-report survey data and preclinical studies, not controlled human trials. ScienceDirect full text was not directly accessible; findings confirmed via publisher/institutional summaries and the study's abstract via search.

From the reference

Browse all compounds →
Testosterone Enanthate
Anabolic steroid
Long-acting ester of the primary endogenous androgen. The reference point every other anabolic compound is described against.
Half-life~4.5 d
SuppressionSevere
HepatotoxicityNone
Nandrolone Decanoate
Anabolic steroid · 19-nor
Added to testosterone protocols for mass and joint comfort. Progestogenic activity and a very long detection window are the cost.
Half-life~7 d
SuppressionSevere
Detection12–18 mo
Anastrozole
Ancillary · aromatase inhibitor
Controls oestradiol on aromatising compounds. Over-suppression is a more frequent problem than under-dosing.
Half-life~46 h
Titrate toSensitive E2
HepatotoxicityLow
3-CMC
Research chemical · cathinone
Substituted cathinone that replaced 3-MMC in several markets after scheduling. Shorter, more compulsive redose pattern.
Onset15–30 min
Duration2–4 h
Addiction riskHigh

Compound index

134 pages · every claim carries an evidence rating

Testosterone esters 719-nortestosterones 5DHT derivatives 9Oral 17α-alkylated 11SARMs 8Peptides & growth hormone 14Ancillaries & PCT 10Incretin agonists 6Substituted cathinones 23Phenethylamines 18Tryptamines 13Benzodiazepine analogues 10
Roidipedia — reference information, not medical advice.